Actively Recruiting
Efficacy and Safety of Intrapulmonary Percussive Ventilation in Patients With Pulmonary Infection Receiving Invasive Mechanical Ventilation
Led by Zhongnan Hospital · Updated on 2026-04-08
96
Participants Needed
1
Research Sites
60 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this clinical trial is to learn whether adding intrapulmonary percussion ventilation (IPV) to standard airway clearance treatment improves clinical outcomes in invasively mechanically ventilated patients with pulmonary infection. It will also evaluate the safety of IPV in this population and assess changes in lung ventilation using electrical impedance tomography (EIT). The main questions it aims to answer are: Does adding IPV shorten the duration of invasive mechanical ventilation compared with standard therapy alone? Does IPV improve regional and global lung ventilation? Does IPV improve clinical indicators, including oxygenation, lung mechanics, and pulmonary infection scores? Is IPV safe in mechanically ventilated patients with pulmonary infection? Participants will: Receive either standard therapy alone or standard therapy plus IPV Undergo serial EIT monitoring at predefined time points Receive routine clinical assessments and ventilator parameter monitoring during ICU stay Be followed until successful weaning, discharge, or completion of hospitalization
CONDITIONS
Official Title
Efficacy and Safety of Intrapulmonary Percussive Ventilation in Patients With Pulmonary Infection Receiving Invasive Mechanical Ventilation
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Diagnosed with pulmonary infection meeting criteria for hospital-acquired pneumonia, ventilator-associated pneumonia, or community-acquired pneumonia based on Chinese guidelines
- Oxygenation index (PaO2/FiO2) of 300 or less
- Currently receiving invasive mechanical ventilation and expected to require it for at least 48 hours
- Written informed consent provided by patient’s family member or legally authorized representative
You will not qualify if you...
- Severe hemodynamic instability requiring norepinephrine dose over 0.5 μg/kg/min
- Markedly elevated intracranial pressure over 25 mmHg or need for strict intracranial pressure control
- Untreated tension pneumothorax or undrained mediastinal emphysema
- Unstable chest wall, flail chest, recent thoracic surgery, or severe thoracic spine injury
- Pregnant or breastfeeding women
- Inability to place the EIT chest belt due to open chest wounds or skin lesions at placement site
- Currently participating in another clinical trial
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Zhongnan Hospital of Wuhan University
Wuhan, Hubei, China, 430071
Actively Recruiting
Research Team
Q
Qingting Xie
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here